Daily Management Review

Recognising The ‘Global Healthcare Challenge’ Glaxo Loosens Its Patents


10/22/2016


GSK seeks for ways to “contribute” in easing “access to medicines” worldwide.



Recognising The ‘Global Healthcare Challenge’ Glaxo Loosens Its Patents
Last week, GlaxoSmithKline, the giant among the “London-listed pharmaceuticals”, reported of its “evolving” approach towards “filing and enforcing patents”, whereby reflecting “a country’s wealth” through “IP protection”.
 
Before the “UN High Level Panel” meeting discussing on “Access to Medicines”, the pharmaceutical informed that it will not “file patents for its medicines” in the countries where the either the income is low or is among the “least developed” countries. In this way, other companies will get a chance to create “cheaper generic versions” of Glaxo’s medicines for selling in those countries.
 
However, when the question comes to the “lower middle income countries”, Glaxo decides to file patent, although it will be offer license or agree to allow license for the sale of “generic versions of its medicines” over a decade. In fact, Glaxo has plans of seeking a small portion of royalty on the above mentioned sales.
 
Eventually, for the “high income”, “upper middle income” as well as G20 countries, Glaxo will maintain its “full patent protection”, while:
“Any Glaxo drugs on the WHO’s list of essential medicines will be included in these changes”.
 
In the words of the chief executive e officer of Glaxo, Sir Andrew Witty:
“In itself, IP is not a barrier to access to medicines. However, we recognise that the global healthcare challenge requires us to be flexible in our approach and responsive to different needs, particularly as the disease burden shifts from infectious to non-communicable diseases.
“We continuously look at ways that GSK can further contribute to increasing access to medicines.”
 
Moreover, Glaxo made an announcement of allowing the “developing countries” to access its “next-generation cancer drugs”, whereby it will allow “competitors to access its intellectual property through the UN-backed Medicines Patent Pool”.
 
 
 
 
 
 
References:
http://www.digitallook.com/







Science & Technology

Germany Introduces The First Ever Train To Run On 100% Hydrogen

Germany Plans On Cyber Security Research To End Reliance On U.S. Tech

Fuchsia will kill Android by 2023: Top 5 facts about the new OS

New Study Finds Goats Interact More With Happy People

More than 32 thousand "smart" houses under threat of hacker attack

Internet addiction and children: Global plague

Apple takes up to develop Apple Watch for health monitoring

Hyperloop is growing in Europe

Analysts: US gamers prefer mobile games

Google Assistant Winner Of Head-To-Head Test Of Digital Assistants, Beats Siri And Alexa

World Politics

World & Politics

Ex-Brexit Minister Said A ‘Reset’ Is Needed For Brexit Talks

10 countries with the best healthcare systems

Foreign Experts To Be Allowed By North Korea For Permanent Destruction Of Missile Sites

Ireland recovers €14.3 billion from Apple

Is China going to cancel its birth limit policy?

The US is ready to start negotiations with China

US and China start 5G race

Is Czech Republic posing a threat to the European Union?